Thrivent Financial for Lutherans trimmed its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 5.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 278,011 shares of the medical research company's stock after selling 14,778 shares during the period. Thrivent Financial for Lutherans owned 0.10% of Agilent Technologies worth $37,348,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently made changes to their positions in A. Flynn Zito Capital Management LLC increased its stake in Agilent Technologies by 3.8% in the fourth quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company's stock valued at $251,000 after purchasing an additional 69 shares in the last quarter. IFP Advisors Inc grew its position in shares of Agilent Technologies by 17.7% during the 4th quarter. IFP Advisors Inc now owns 458 shares of the medical research company's stock valued at $62,000 after acquiring an additional 69 shares during the period. Tiemann Investment Advisors LLC increased its position in Agilent Technologies by 5.6% in the fourth quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company's stock worth $191,000 after buying an additional 75 shares during the last quarter. Brown Brothers Harriman & Co. boosted its position in Agilent Technologies by 13.5% during the third quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company's stock worth $96,000 after purchasing an additional 77 shares during the period. Finally, Rothschild Investment LLC grew its stake in Agilent Technologies by 19.2% in the 4th quarter. Rothschild Investment LLC now owns 491 shares of the medical research company's stock valued at $66,000 after buying an additional 79 shares in the last quarter.
Wall Street Analyst Weigh In
A has been the topic of a number of research analyst reports. Bank of America decreased their price target on shares of Agilent Technologies from $153.00 to $150.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. JPMorgan Chase & Co. lowered their price target on Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating for the company in a research report on Tuesday, November 26th. StockNews.com upgraded Agilent Technologies from a "hold" rating to a "buy" rating in a report on Tuesday, December 24th. Robert W. Baird reduced their target price on Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Finally, Sanford C. Bernstein cut their price target on shares of Agilent Technologies from $140.00 to $135.00 and set a "market perform" rating on the stock in a report on Tuesday, November 26th. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Agilent Technologies has a consensus rating of "Moderate Buy" and a consensus target price of $146.15.
Get Our Latest Stock Report on A
Agilent Technologies Stock Up 1.0 %
Shares of Agilent Technologies stock traded up $1.21 during trading on Monday, hitting $121.96. The company's stock had a trading volume of 1,557,412 shares, compared to its average volume of 1,684,041. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. The company has a fifty day simple moving average of $136.74 and a two-hundred day simple moving average of $137.28. Agilent Technologies, Inc. has a 52 week low of $117.17 and a 52 week high of $155.35. The company has a market capitalization of $34.77 billion, a PE ratio of 28.04, a P/E/G ratio of 3.39 and a beta of 1.11.
Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. The company had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Equities research analysts predict that Agilent Technologies, Inc. will post 5.57 earnings per share for the current year.
Agilent Technologies Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a yield of 0.81%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies's dividend payout ratio (DPR) is 22.76%.
Insider Activity at Agilent Technologies
In other Agilent Technologies news, VP Rodney Gonsalves sold 1,908 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the transaction, the vice president now owns 21,786 shares of the company's stock, valued at approximately $2,657,456.28. The trade was a 8.05 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Padraig Mcdonnell sold 1,911 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the transaction, the chief executive officer now owns 39,652 shares in the company, valued at $5,947,800. This represents a 4.60 % decrease in their position. The disclosure for this sale can be found here.
About Agilent Technologies
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Featured Articles
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
